MA33299B1 - Nouvelle formulation de naproxène - Google Patents

Nouvelle formulation de naproxène

Info

Publication number
MA33299B1
MA33299B1 MA34386A MA34386A MA33299B1 MA 33299 B1 MA33299 B1 MA 33299B1 MA 34386 A MA34386 A MA 34386A MA 34386 A MA34386 A MA 34386A MA 33299 B1 MA33299 B1 MA 33299B1
Authority
MA
Morocco
Prior art keywords
naproxen
new formula
compositions
methods
relates
Prior art date
Application number
MA34386A
Other languages
Arabic (ar)
English (en)
French (fr)
Inventor
Felix Meiser
Marck Norret
Adrian Russell
H William Bosch
Aaron Dodd
Original Assignee
Iceutica Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2009901746A external-priority patent/AU2009901746A0/en
Application filed by Iceutica Pty Ltd filed Critical Iceutica Pty Ltd
Publication of MA33299B1 publication Critical patent/MA33299B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/02Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA34386A 2009-04-24 2010-04-23 Nouvelle formulation de naproxène MA33299B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17228909P 2009-04-24 2009-04-24
AU2009901746A AU2009901746A0 (en) 2009-04-24 A Novel Formulation of Naproxen
PCT/AU2010/000470 WO2010121326A1 (en) 2009-04-24 2010-04-23 A novel formulation of naproxen

Publications (1)

Publication Number Publication Date
MA33299B1 true MA33299B1 (fr) 2012-05-02

Family

ID=43010609

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34386A MA33299B1 (fr) 2009-04-24 2010-04-23 Nouvelle formulation de naproxène

Country Status (19)

Country Link
US (5) US20120148634A1 (enExample)
EP (1) EP2421512A4 (enExample)
JP (2) JP6116244B2 (enExample)
KR (3) KR20160135370A (enExample)
CN (2) CN102438592B (enExample)
AP (1) AP3530A (enExample)
AU (1) AU2010239085C1 (enExample)
CA (1) CA2759122A1 (enExample)
CO (1) CO6470806A2 (enExample)
EA (1) EA201171284A1 (enExample)
IL (1) IL215868A0 (enExample)
MA (1) MA33299B1 (enExample)
MX (1) MX344222B (enExample)
NZ (2) NZ595985A (enExample)
SG (2) SG175767A1 (enExample)
TN (1) TN2011000536A1 (enExample)
UA (1) UA111578C2 (enExample)
WO (1) WO2010121326A1 (enExample)
ZA (1) ZA201108648B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2054042B8 (en) 2006-06-30 2020-06-10 iCeutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
MY159208A (en) 2009-04-24 2016-12-30 Iceutica Pty Ltd A novel formulation of indomethacin
SG10201607849TA (en) * 2009-04-24 2016-11-29 Iceutica Pty Ltd Production of encapsulated nanoparticles at commercial scale
KR101794032B1 (ko) * 2011-09-21 2017-11-07 (주)바이오시네틱스 나노입자 제조방법
WO2015179098A1 (en) 2014-05-21 2015-11-26 Integenx Inc. Fluidic cartridge with valve mechanism
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
US11175268B2 (en) 2014-06-09 2021-11-16 Biometry Inc. Mini point of care gas chromatographic test strip and method to measure analytes
US11435340B2 (en) 2014-06-09 2022-09-06 Biometry Inc. Low cost test strip and method to measure analyte
GB201506755D0 (en) 2015-04-21 2015-06-03 Reckitt Benckiser Llc Novel pharmaceutical formulation
US10210410B2 (en) 2014-10-22 2019-02-19 Integenx Inc. Systems and methods for biometric data collections
US10690627B2 (en) 2014-10-22 2020-06-23 IntegenX, Inc. Systems and methods for sample preparation, processing and analysis
CA3001337C (en) 2015-10-09 2023-12-12 Reckitt Benckiser Llc Pharmaceutical formulation
DK3411031T3 (da) 2016-02-04 2024-10-21 Cindome Pharma Inc Deutererede domperidonpræparater og fremgangsmåder til terapi af lidelser
JP7086927B2 (ja) 2016-07-19 2022-06-20 バイオメトリー・インコーポレイテッド バッチ校正可能なテストストリップを用いる検体測定方法と検体測定システム
JP7163015B2 (ja) * 2016-10-31 2022-10-31 エスエス製薬株式会社 経口固形組成物
EP3613415B1 (en) * 2017-04-21 2022-11-09 Bio-Synectics Inc. Method for preparing active material nanoparticles using lipid as lubricant for milling
KR20240125702A (ko) 2017-06-30 2024-08-19 신돔 파마, 인크. 중수소화 돔페리돈 조성물, 방법, 및 제조
US12478612B2 (en) 2017-06-30 2025-11-25 Cindome Pharma, Inc. Deuterated domperidone compositions, methods, and preparation
US11779541B2 (en) * 2019-03-26 2023-10-10 Johnson & Johnson Consumer Inc. Immediate release dosage form
TW202241409A (zh) * 2020-12-18 2022-11-01 南韓商大熊製藥股份有限公司 包含1-(5-(2,4-二氟苯基)-1-((3-氟苯基)磺醯基)-4-甲氧基-1h-吡咯-3-基)-n-甲基甲胺之用於經口投予的新調配物
KR20250112022A (ko) * 2024-01-16 2025-07-23 피투케이바이오 주식회사 리바록사반 흡입용 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2642486B2 (ja) * 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
WO1998035666A1 (en) * 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
US20030087308A1 (en) * 2001-06-22 2003-05-08 Elan Pharma International Limited Method for high through put screening using a small scale mill or microfluidics
CA2858733C (en) * 2004-12-31 2017-12-19 Iceutica Pty Ltd Nanoparticle compositions and methods for synthesis thereof
EP2054042B8 (en) * 2006-06-30 2020-06-10 iCeutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
US20100003332A1 (en) * 2006-07-27 2010-01-07 Amorepacific Corporation Process For Preparing Powder Comprising Nanoparticles of Sparingly Soluble Drug
SG10201607849TA (en) * 2009-04-24 2016-11-29 Iceutica Pty Ltd Production of encapsulated nanoparticles at commercial scale
EA201171282A1 (ru) * 2009-04-24 2012-05-30 Айсьютика Пти Лтд. Способ производства коммерческих порошков, содержащих нано- и микрочастицы
WO2010121321A1 (en) * 2009-04-24 2010-10-28 Iceutica Pty Ltd Method for improving the dissolution profile of a biologically active material
KR20150032759A (ko) * 2009-04-24 2015-03-27 아이슈티카 피티와이 리미티드 큰 용적 분율로 캅셀화된 나노입자의 생산

Also Published As

Publication number Publication date
IL215868A0 (en) 2012-01-31
ZA201108648B (en) 2013-01-30
KR20160135370A (ko) 2016-11-25
US20150087709A1 (en) 2015-03-26
US20120148634A1 (en) 2012-06-14
SG10201401720RA (en) 2014-06-27
US20150313857A1 (en) 2015-11-05
AU2010239085A1 (en) 2011-11-10
CN103877030A (zh) 2014-06-25
AP2011005991A0 (en) 2011-12-31
WO2010121326A1 (en) 2010-10-28
US20160220518A1 (en) 2016-08-04
NZ626401A (en) 2015-12-24
NZ595985A (en) 2014-07-25
UA111578C2 (uk) 2016-05-25
KR20120104489A (ko) 2012-09-21
KR20150008909A (ko) 2015-01-23
JP2015166379A (ja) 2015-09-24
MX344222B (es) 2016-12-07
AP3530A (en) 2016-01-13
US20140200276A1 (en) 2014-07-17
AU2010239085B2 (en) 2014-07-03
EA201171284A1 (ru) 2012-05-30
CN102438592B (zh) 2016-09-14
CO6470806A2 (es) 2012-06-29
MX2011011220A (es) 2012-02-08
EP2421512A4 (en) 2013-01-23
JP6116244B2 (ja) 2017-04-19
JP2012524722A (ja) 2012-10-18
EP2421512A1 (en) 2012-02-29
TN2011000536A1 (en) 2013-05-24
JP6177275B2 (ja) 2017-08-09
AU2010239085C1 (en) 2014-10-16
CN102438592A (zh) 2012-05-02
SG175767A1 (en) 2011-12-29
CA2759122A1 (en) 2010-10-28

Similar Documents

Publication Publication Date Title
MA33299B1 (fr) Nouvelle formulation de naproxène
MA33292B1 (fr) Production de nanoparticules encapsulees a des fins commerciales
MA33296B1 (fr) Nouvelle formulation d'indométhacine
MA33295B1 (fr) Nouvelle formulation de diclofénac
MA33297B1 (fr) Production de nanoparticules encapsulées à des fractions volumiques élevées
MA35567B1 (fr) Nouvelle formulation de méloxicam
MA34765B1 (fr) Antagonistes des récepteurs de l'acide lysophosphatidique et utilisations de ceux-ci
MA34449B1 (fr) Formulation de poudre seche comprenant un inhibiteur de phosphodiesterase
MA38146B1 (fr) Nouveaux dérivés du benzimidazole comme antagonistes ep4
MA33467B1 (fr) Promédicaments comprenant un conjugué insuline-lieur
MX2011011233A (es) Una formulacion novedosa de metaxalona.
MA34721B1 (fr) Acides carboxyliques 1-benzylcycloalkyle substitués et leur utilisation
MA37610B1 (fr) Formulations de testostérone proliposomales
MA34474B1 (fr) Agonistes de gpr40
MA32226B1 (fr) Compositions et leurs procedes de preparation et d'utilisation
EP2257161A4 (en) AHCY-HYDROLASE INHIBITOR FOR THE TREATMENT OF HYPERHOMOCYSTEINEMIA
NO20076405L (no) Anvendelse av 24-nor-UDCA
MA37524B1 (fr) Procedes de production de chlorhydrate d'anamoreline presentant une teneur en chlorure regulee
EP2073635A4 (en) MACROCYCLIC SPIROPIPERIDINE BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF MORBUS ALZHEIMER
MA33512B1 (fr) Inhibiteurs de la cathepsine c
AU2014208310B2 (en) A Novel Formulation of Diclofenac
EP1912963A4 (en) CYCLIC KETALS AS BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
MX2009002717A (es) Composiciones y metodos para tratamiento del sindrome de fatiga cronica y enfermedades neurodegenerativas.
MA37957A1 (fr) Procédés de traitement de la maladie d'alzheimer et compositions pharmaceutiques associées
MA38655A1 (fr) Nouveaux composés destinés au traitement du cancer